Literature DB >> 10566730

Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease.

E Battaglia1, L Biancone, A Resegotti, G Emanuelli, G R Fronda, G Camussi.   

Abstract

OBJECTIVE: Selected mechanisms of the immune system participate in the development of inflammatory bowel disease. Recently, overexpression of the ligand for CD40 (CD40L), a lymphocyte costimulatory molecule, was shown to induce severe inflammatory bowel disease in transgenic mice. In the present study, we examined the expression of CD40 and CD40L on surgical specimens of ileum from 12 patients with Crohn's disease and 10 patients with diverticulitis.
METHODS: Several CD40L+ cells were present in the affected tissue of patients with Crohn's disease, whereas few scattered CD40L+ cells were detected in sections of histologically normal ileum, resected distantly from the affected tissue, in patients with diverticulitis and in normal ileum portions obtained from colorectal cancer undergoing extensive surgery. The phenotype of CD40L+ cells was mainly CD4+.
RESULTS: In patients with Crohn's disease, several CD40+ cells were detectable in the same areas of lymphocytes expressing CD40L, whereas in patients with diverticulitis, the number of CD40+ cells was significantly lower. Most of the CD40+ cells costained with CD20, thus showing to be B-lymphocytes, and only a few were CD14+ macrophages. Several von Willebrand-positive vessels were also positive for CD40. In addition, several infiltrating macrophages were found to express B7-1 and B7-2 molecules, the ligands of CD28 and CTLA-4, which cooperate with the CD40-CD40L pathway in lymphocyte activation. Staining of ileal lesions with anti-CTLA-4 antibodies resulted in detection of none or very few positive cells. In contrast, in patients with diverticulitis, an enhanced number of B7-1 and B7-2 and CTLA-4 was observed.
CONCLUSION: The local accumulation of CD40L+ together with CD40+ cells within intestinal lesions of Crohn's disease suggests the involvement of this co-stimulatory pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566730     DOI: 10.1111/j.1572-0241.1999.01538.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  27 in total

Review 1.  The CD40/CD40L costimulatory pathway in inflammatory bowel disease.

Authors:  S Danese; M Sans; C Fiocchi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

2.  Murine AIDS requires CD154/CD40L expression by the CD4 T cells that mediate retrovirus-induced disease: Is CD4 T cell receptor ligation needed?

Authors:  Wen Li; William R Green
Journal:  Virology       Date:  2006-11-17       Impact factor: 3.616

3.  Persistence of high CD40 and CD40L expression after restorative proctocolectomy for ulcerative colitis.

Authors:  Lino Polese; Imerio Angriman; De Franchis Giuseppe; Attilio Cecchetto; Giacomo-C Sturniolo; D'Inca Renata; Marco Scarpa; Cesare Ruffolo; Lorenzo Norberto; Mauro Frego; Davide-F D'Amico
Journal:  World J Gastroenterol       Date:  2005-09-14       Impact factor: 5.742

4.  Proinflammatory cytokine synthesis by mucosal fibroblasts from mouse colitis is enhanced by interferon-gamma-mediated up-regulation of CD40 signalling.

Authors:  T De L Karlson; C V Whiting; P W Bland
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

5.  Tumour necrosis factor-alpha production stimulated by heat shock protein 70 and its inhibition in circulating dendritic cells and cells eluted from mucosal tissues in Crohn's disease.

Authors:  T Whittall; Y Wang; C G Kelly; R Thompson; J Sanderson; M Lomer; S Y Soon; L A Bergmeier; M Singh; T Lehner
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

6.  Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease.

Authors:  D C Baumgart; S Thomas; I Przesdzing; D Metzke; C Bielecki; S M Lehmann; S Lehnardt; Y Dörffel; A Sturm; A Scheffold; J Schmitz; A Radbruch
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

7.  Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease.

Authors:  B Szebeni; G Veres; A Dezsõfi; K Rusai; A Vannay; M Mraz; E Majorova; A Arató
Journal:  Clin Exp Immunol       Date:  2007-11-07       Impact factor: 4.330

8.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 9.  Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis.

Authors:  Kazuichi Okazaki; Hiroshi Nakase; Norihiko Watanabe; Yasuhiko Tabata; Yoshito Ikada; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

10.  CD40: novel association with Crohn's disease and replication in multiple sclerosis susceptibility.

Authors:  Fiona Blanco-Kelly; Fuencisla Matesanz; Antonio Alcina; María Teruel; Lina M Díaz-Gallo; María Gómez-García; Miguel A López-Nevot; Luis Rodrigo; Antonio Nieto; Carlos Cardeña; Guillermo Alcain; Manuel Díaz-Rubio; Emilio G de la Concha; Oscar Fernandez; Rafael Arroyo; Javier Martín; Elena Urcelay
Journal:  PLoS One       Date:  2010-07-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.